Red Tide Blood Builder Injection 10ml

Red Tide Blood Builder Injection 10mL  may naturally aid in the body’s normal function of healthy building up of blood cells. Dosing and frequency of supplementation can vary under certain circumstances due to alterations in absorption.

Buy Red Tide Blood Builder Injection (RTBB)

Red Tide Blood Builder Injection 10mL may naturally aid in the body’s normal function of healthy building up of blood cells. Dosing and frequency of supplementation can vary under certain circumstances due to alterations in absorption.

Presentation for Red Tide Blood Builder Injection 10mL:

10ml sterile bottle.

Administration for Red Tide Blood Builder Injection 10mL:

Best used four to five days prior to event. Effects last for three to four weeks.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Red Tide Blood Builder Injection  Red Tide Blood Builder Injection

Red Tide Blood Builder Injection 10mL is a novel compound with very important properties which can be of great use in the animal world. RTBB has been researched for its positive qualities in the research area of treating anemia in chronic kidney disease conditions by building up blood cells as well as is being researched for utilization in a cancer setting with promising results thus far. RTBB is an “EPO-mimetic peptide, a synthetic PEGylated peptidic erythropoiesis stimulating agent (ESA)” and something of great interest that has been noted is that RTBB is a “dimeric peptide conjugated to a polymeric polyethylene glycol moiety with a sequence completely unrelated to erythropoietin (EPO)”. Although the structure differs from erythropoietin, it is very efficient in binding to the EPO receptors and promoting erythropoiesis through a common pathway that other less effective and more risky ESAs activate as well. RTBB binds and activates the erythropoietin receptor and causes proliferation and differentiation of erythroid progenitor cells much like other compounds of this nature. This is a truly ground breaking compound since the first utilization and research of erythropoientins from over 20 years ago.

Some may be wondering “why does it matter if it’s not the same structure as first generation compounds of this class?” well RTBB not only has great action in blood building properties, but also has a fairly long active life after administration and of even greater importance is that RTBB also hasn’t shown a problematic increase in anti-bodies like other ESAs have. Antibodies with compounds of this class can have very detrimental effects. It has been found that;

“Animals administered marketed ESAs develop anti-EPO antibodies that null the effect of the administered ESA and neutralize endogenous EPO, resulting in severe anemia that precludes the interpretation of chronic safety studies.” This pretty much means the subject could end up being worse off than before treatment was first started. With RTBB we can even correct these issues by transitioning over to RTBB from